Bioactive Products
| A unique collection of 51 Anti-platelet aggregation natural compounds | ||
| Catalog No: | B24 | Anti-platelet-aggregation Compound Library Screening Details |
| Size: | 1mg/well * 51 Compounds 2mg/well * 51 Compounds | |
| Cat. No. | Information |
| CFN92409 | Norjuziphine Norjuziphine has antiplatelet aggregation activity. |
| CFN92417 | Cyclomulberrin Cyclomulberrin shows strong inhibition of arachidonic acid (AA)- and collagen-induced platelet aggregation, it also shows slight but significant antiplatelet effects on the aggregation induced by PAF. Cyclomulberrin enhances cell viability in a dose-dependent manner against sodium nitroprusside-induced cell death in neuroblastoma SH-SY5Y cells. It exhibits potent inhibition of human PLC/PRF/5 and KB cells in-vitro. |
| CFN92418 | Cyclocommunol Cyclocommunol exhibits cytotoxicity against hepatocellular carcinoma (SMMC-7721) and gastric carcinoma (BGC-823 and SGC-7901) cell lines. It also shows strong inhibition of arachidonic acid (AA)- and collagen-induced platelet aggregation. |
| CFN92425 | Gnetol Gnetol significantly suppresses melanin biosynthesis in murine B16 melanoma cells, it has a strong inhibitory effect on murine tyrosinase activity. Gnetol is active in the inhibition of arachidonic acid (AA)-induced platelet aggregation.Gnetol has the IC(50) value of 1.3 uM towards butyrylcholinesterase and shows a reversible and competitive inhibition in the kinetic study. |
| CFN92431 | Kazinol A Kazinol A shows strong inhibition of arachidonic acid (AA)-induced platelet aggregation. It also exhibits potent inhibition with IC50 values ranging 0.6–164 M against XOD. Kazinol A may be a candidate for the development of effective anti-cancer drug on human urinary bladder cancer, it induces cytotoxic effects in human bladder cancer cells, including the cisplatin-resistant T24R2. |
